Eton Pharmaceuticals (NASDAQ:ETON - Free Report) had its price objective boosted by HC Wainwright from $15.00 to $17.00 in a research report sent to investors on Monday, Marketbeat reports. They currently have a buy rating on the stock.
Separately, Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, October 28th.
View Our Latest Stock Analysis on Eton Pharmaceuticals
Eton Pharmaceuticals Price Performance
Shares of NASDAQ:ETON traded down $0.84 on Monday, hitting $12.16. The company's stock had a trading volume of 452,312 shares, compared to its average volume of 446,571. The company has a market capitalization of $316.78 million, a PE ratio of -55.27 and a beta of 1.38. The company has a 50-day simple moving average of $11.36 and a 200 day simple moving average of $7.16. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $15.00.
Hedge Funds Weigh In On Eton Pharmaceuticals
Several institutional investors have recently modified their holdings of ETON. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals during the third quarter valued at approximately $54,000. Jane Street Group LLC purchased a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at $90,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company's stock valued at $390,000 after purchasing an additional 30,167 shares during the last quarter. Renaissance Technologies LLC raised its position in Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock worth $350,000 after purchasing an additional 41,469 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in Eton Pharmaceuticals in the 2nd quarter worth $362,000. 27.86% of the stock is currently owned by institutional investors.
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Recommended Stories
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
